Scientific Opinion on the substantiation of health claims related to alpha cyclodextrin and reduction of post prandial glycaemic responses (ID 2926, further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

EFSA Journal

Volumn 10, Issue 6, 2012, Pages

[No Author Info available]

Author keywords

alpha Cyclodextrin; glycaemic response; health claims

Indexed keywords

EID: 84977133539     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2012.2713     Document Type: Article

References (18)

1. Buckley JD, Thorp AA, Murphy KJ and Howe PR, 2006. Dose-dependent inhibition of the post-prandial glycaemic response to a standard carbohydrate meal following incorporation of alpha-cyclodextrin. Annals of Nutrition and Metabolism, 50, 108–114.
2. Comerford KB, Artiss JD, Jen KL and Karakas SE, 2011. The beneficial effects of alpha-cyclodextrin on blood lipids and weight loss in healthy humans. Obesity (Silver Spring), 19, 1200–1204.
3. Diamantis I and Bär A, 2002a. Effect of alpha-cyclodextrin on the glycemic index (GI) and insulinemic index (II) of starch in human volunteers. Unpublished study protocol.
4. Diamantis I and Bär A, 2002b. Effect of alpha-cyclodextrin on the glycaemic index (GI) and insulinaemic index (II) of starch in healthy human volunteers. Unpublished study report.
5. EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010. Scientific Opinion on the substantiation of health claims related to alpha cyclodextrin and reduction of post prandial glycaemic responses (ID 856, 2926), maintenance or achievement of a normal body weight (ID 2925) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal, 8(2):1479, 13 pp.
6. Gentilcore D, Vanis L, Teng JC, Wishart JM, Buckley JD, Rayner CK, Horowitz M and Jones KL, 2011. The oligosaccharide alpha-cyclodextrin has modest effects to slow gastric emptying and modify the glycaemic response to sucrose in healthy older adults. British Journal of Nutrition, 106, 583–587.
7. Grunberger G, Jen KL and Artiss JD, 2007. The benefits of early intervention in obese diabetic patients with FBCx: a new dietary fibre. Diabetes/Metabolism Research and Reviews, 23, 56–62.
8. Koukiekolo R, Desseaux V, Moreau Y, Marchis-Mouren G and Santimone M, 2001. Mechanism of porcine pancreatic alpha-amylase. Inhibition of amylose and maltopentaose hydrolysis by alpha-, beta- and gamma-cyclodextrins. European Journal of Biochemistry, 268, 841–848.
9. Larson SB, Greenwood A, Cascio D, Day J and McPherson A, 1994. Refined molecular structure of pig pancreatic alpha-amylase at 2.1 A resolution. Journal of Molecular Biology, 235, 1560–1584.
10. Larson SB, Day JS and McPherson A, 2010. X-ray crystallographic analyses of pig pancreatic alpha-amylase with limit dextrin, oligosaccharide, and alpha-cyclodextrin. Biochemistry, 49, 3101–3115.
11. Li S, Shin HJ, Ding EL and van Dam RM, 2009. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA, 302, 179–188.
12. Ochiai H, Ooka H, Shida C, Ishikawa T, Inoue D and Okazaki R, 2008. Acarbose treatment increases serum total adiponectin levels in patients with type 2 diabetes. Endocrine Journal, 55, 549–556.
13. Oudjeriouat N, Moreau Y, Santimone M, Svensson B, Marchis-Mouren G and Desseaux V, 2003. On the mechanism of alpha-amylase. European Journal of Biochemistry, 270, 3871–3879.
14. Rejzek M, Stevenson CE, Southard AM, Stanley D, Denyer K, Smith AM, Naldrett MJ, Lawson DM and Field RA, 2011. Chemical genetics and cereal starch metabolism: structural basis of the non-covalent and covalent inhibition of barley beta-amylase. Molecular Biosystems, 7, 718–730.
15. Shimazu T, Inami N, Satoh D, Kajiura T, Yamada K, Iwasaka T and Nomura S, 2009. Effect of acarbose on platelet-derived microparticles, soluble selectins, and adiponectin in diabetic patients. Journal of Thrombosis and Thrombolysis, 28, 429–435.
16. Venn BJ and Green TJ, 2007. Glycemic index and glycemic load: measurement issues and their effect on diet-disease relationships. European Journal of Clinical Nutrition, 61 Suppl 1, S122–131.
17. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE and Tataranni PA, 2001. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. Journal of Clinical Endocrinology and Metabolism, 86, 1930–1935.
18. Yun JE, Sull JW, Lee HY, Park E, Kim S, Jo J, Lee SJ, Kim SY, Choi YJ, Jee SH and Huh KB, 2009. Serum adiponectin as a useful marker for metabolic syndrome in type 2 diabetic patients. Diabetes/Metabolism Research and Reviews, 25, 259–265.